Cellectar opens manufacturing facility for radiolabeled CLR1404

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 1
Volume 17
Issue 1

Cellectar opens manufacturing facility for radiolabeled CLR1404

MADISON, Wisconsin-Cellectar has opened its new $3.3 million radiopharmaceutical research, development, and manufacturing facility and headquarters in Madison. The facility allows Cellectar to manufacture and radiolabel its lead compound CLR1404, a phospholipid ether combined with 131Iodine, in compliance with Good Manufacturing Practices.

Recent Videos
Related Content